Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiangiogenic therapy]

M Toi1

  • 1Dept. of Surgery, Tokyo Metropolitan Komagome Hospital, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 5, 1998
PubMed
Summary

Targeting tumor vasculature with antiangiogenic treatments shows promise for cancer therapy. This review covers novel inhibitors and early clinical results of these agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

ESMO open·2024
Same author

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

ESMO open·2024
Same author

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Discovery

Context:

  • Tumor vasculature is a critical target for novel anticancer strategies.
  • Endogenous inhibitors like angiostatin and synthetic compounds are being developed.
  • Numerous antiangiogenic agents are in pre-clinical and early clinical trials.

Purpose:

  • To provide a comprehensive overview of antiangiogenic treatments.
  • To summarize early clinical outcomes of agents targeting tumor vasculature.
  • To highlight the potential of antiangiogenic therapies in cancer treatment.

Summary:

  • This review examines the development of natural and synthetic products targeting tumor vasculature.
  • It analyzes endogenous inhibitors and compounds currently under investigation.
  • The focus is on antiangiogenic therapies and their initial clinical results.

Impact:

  • Antiangiogenic treatments represent a promising frontier in oncology.
  • Understanding early clinical results informs future therapeutic development.
  • Targeting tumor blood vessel formation offers a novel approach to cancer treatment.

Related Experiment Videos